Sun Pharma secures more than two years of Section 232 tariff relief in its US pricing agreement

On Aug. 31, 2026, the Trump administration announced a new round of drug-pricing agreements with international pharmaceutical companies and smaller biotechs, including Sun Pharmaceutical, Astellas, BeOne Medicines, CSL, BridgeBio and UCB ^[1]. The companies agreed to offer drugs to state Medicaid programs at most-favored-nation prices, according to President Trump, who called the arrangement "a tremendous discount" for patients ^[1].

The White House did not release details of the agreements, and it is not clear how many drugs are covered or at what discount, so the actual savings for the government or for patients remain unknown ^[1]. Some companies described parts of their deals as private ^[1]. Reuters reporting does not specify the length of tariff relief tied to the Sun Pharmaceutical agreement, and a Facebook post cited as a separate source describing the deal's terms was not accessible for verification, so the precise duration of any Section 232 tariff exemption for Sun Pharmaceutical is not confirmed here.

The new deals follow agreements the administration struck last year with 17 of the world's largest drugmakers, including Pfizer, Eli Lilly and Novo Nordisk ^[1]. Those companies agreed to cut some prices for federal health programs and sell certain medicines directly to patients through a Trump-branded website, in exchange for tariff relief ^[1]. Reuters reports that the biggest savings from those earlier deals have come from weight-loss drugs, with Novo Nordisk and Eli Lilly agreeing to price cuts tied to broader availability of their medicines through Medicare ^[1].

Centers for Medicare & Medicaid Services Administrator Mehmet Oz said Monday that 600,000 seniors have sought prescriptions through a temporary Medicare pilot for weight-loss drugs that began July 1 ^[1]. Consumer advocacy group Public Citizen has questioned how much real price relief Americans are seeing overall. Its Access to Medicines director, Peter Maybarduk, said in a statement that "the new deals are a distraction from the administration's failed plan to lower U.S. drug prices to the levels paid in other wealthy countries," noting that Medicaid already gets steep discounts under existing law and most Medicaid enrollees pay little out of pocket ^[1].

Why it matters for patients

For people taking or considering semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound), the relevant fact is the underlying trade: drugmakers get relief from Section 232 tariffs in exchange for agreeing to lower some prices and expand access through federal programs ^[1]. That trade, first struck with Lilly and Novo Nordisk, is now being repeated with other companies, though Sun Pharmaceutical is not primarily known as a GLP-1 manufacturer in the U.S. market based on the available reporting. The Medicare pilot that began July 1 has already drawn interest from 600,000 seniors seeking weight-loss drug prescriptions, according to CMS ^[1]. Patients should not assume these deals immediately change list prices or insurance coverage, since the White House has not disclosed which drugs or discounts are covered, and outside groups dispute how meaningful the savings are ^[1].

What happens next

Teva, which attended Monday's event, said it is still negotiating a possible agreement with the administration ^[1]. The administration has said its broader pricing push, including the earlier large-company deals, could save $64.3 billion in federal and state spending over the next decade, though Reuters describes that figure as speculative ^[1]. Reuters also notes the administration has staged several high-profile events with drug company executives this year as part of a broader affordability push ahead of the midterm elections that will decide control of Congress ^[1]. No dated milestone for Sun Pharmaceutical's specific tariff terms taking effect is given in available reporting.